Table 3 Drug consumption at first year of follow-up

Palivizumab

527

48.6%**

45.6

51.6

235

7.2%

6.3

8.0

419

11.0%

10.0

11.9

 Early preterm

288

78.7%

74.5

82.9

15

71.4%

52.1

90.8

32

47.8%

35.8

59.7

 Moderate-late preterm

239

33.3%

29.8

36.7

109

21.5%

17.9

25.1

387

10.3%

9.3

11.3

 Born at term

-

111

4.0%

3.3

4.8

-

Antibacterials for systemic use

426

39.3%

36.4

42.2

1368

41.6%

39.9

43.3

1498

39.2%*

37.6

40.7

Adrenergics. inhalants

329

30.4%**

27.6

33.1

786

23.9%

22.5

25.4

909

23.8%

22.4

25.1

Glucocorticoids for obstructive airway diseases, inhalants

342

31.5%

28.8

34.3

1047

31.9%

30.3

33.5

1114

29.1%*

27.7

30.6

Glucocorticoids for systemic use

225

20.8%**

18.3

23.2

512

15.6%

12.4

18.7

593

15.5%

14.3

16.7